EGFR and non-small cell lung carcinoma: Osimertinib, which inhibits both EGFR sensitizing mutations and T790M, a common resistance mutation in EGFR mutated NSCLC, was approved in 2020 in the United States, however, is not listed in the WHO MLEM at present.